Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

What Was Tested

Researchers studied Exenatide in this randomized controlled trial publication.

The objective of this study was to evaluate the effects of > or = 3 years exenatide therapy on glycemic control, body weight, cardiometabolic markers, and safety.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Patients from three placebo-controlled trials and their open-label extensions were enrolled into one open-ended, open-label clinical trial.

Patients were randomized to twice daily (BID) placebo, 5 mug exenatide, or 10 mug exenatide for 30 weeks, followed by 5 mug exenatide BID for 4 weeks, then 10 mug exenatide BID for > or = 3 years of exenatide exposure.

How the Study Was Run

In design terms this was a randomized, open-label and placebo-controlled study.

The participants were allocated by chance, so the Exenatide group and the comparison group should start out alike.

Everyone knew when Exenatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

A placebo (an inactive look-alike) gave the Exenatide group a baseline to be compared against.

The methods mention a period of 30 weeks.

Patients continued metformin and/or sulfonylureas.

What Was Measured

The subject headings attached to it are Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Exenatide, Glycated Hemoglobin, Hypoglycemic Agents and Liver.

What This Means in Plain Language

The paper is a randomized, open-label and placebo-controlled study of Exenatide over 30 weeks.

Its findings take up roughly 12 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2008 (Current medical research and opinion), a journal based in England.

More context: the Exenatide compound page.